Expression of LRIG1 is associated with good prognosis and human papillomavirus status in oropharyngeal cancer

British Journal of Cancer

Volumn 110, Issue 7, 2014, Pages 1793-1800

  Lindquist, D ^a   Nasman A ^b   Tarjan M ^c   Henriksson, R ^a   Tot, T ^c   Dalianis, T ^b   Hedman, H ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c FALUN HOSPITAL   (Sweden)

Author keywords

CD44; HPV; LRIG1; p16

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; HERMES ANTIGEN; LEUCINE RICH REPEATS AND IMMUNOGLOBULIN LIKE DOMAIN 1; LEUCINE RICH REPEATS AND IMMUNOGLOBULIN LIKE DOMAIN 2; PROTEIN P16; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN DOMAIN PROTEIN 1; LEUCINE RICH REPEAT AND IMMUNOGLOBULIN DOMAIN PROTEIN 2;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; OROPHARYNX CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; SWEDEN; TONGUE CANCER; TONSIL CANCER; UNIVARIATE ANALYSIS; WART VIRUS; COHORT ANALYSIS; TONGUE; TONSIL;

ADULT; AGED; AGED, 80 AND OVER; COHORT STUDIES; FEMALE; HUMANS; IMMUNOASSAY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; OROPHARYNGEAL NEOPLASMS; PAPILLOMAVIRUS INFECTIONS; PROGNOSIS; SURVIVAL ANALYSIS; SWEDEN; TUMOR MARKERS, BIOLOGICAL;

EID: 84897571254     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2014.87     Document Type: Article

References (38)

1. Attner P, Du J, Nasman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T, Munck-Wikland E (2010) The role of human papillomavirus in the increased incidence of base of tongue cancer. Int J Cancer 126: 2879-2884.
2. Attner P, Du J, Nasman A, Hammarstedt L, Ramqvist T, Lindholm J, Marklund L, Dalianis T, Munck-Wikland E (2011) Human papillomavirus and survival in patients with base of tongue cancer. Int J Cancer 128: 2892-2897.
3. Bonner JA, Harari PM, Giralt J (2010) Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 11: 21-28.
4. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM (2010) Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 127: 2893-2917.
5. Guo D, Holmlund C, Henriksson R, Hedman H (2004) The LRIG gene family has three vertebrate paralogs widely expressed in human and mouse tissues and a homolog in Ascidiacea. Genomics 84: 157-165.
6. Guo D, Nilsson J, Haapasalo H, Raheem O, Bergenheim T, Hedman H, Henriksson R (2006) Perinuclear leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) as prognostic indicators in astrocytic tumors. Acta Neuropathol 111: 238-246.
7. Gur G, Rubin C, Katz M, Amit I, Citri A, Nilsson J, Amariglio N, Henriksson R, Rechavi G, Hedman H, Wides R, Yarden Y (2004) LRIG1 restricts growth factor signaling by enhancing receptor ubiquitylation and degradation. EMBO J 23: 3270-3281.
8. Hammarstedt L, Lindquist D, Dahlstrand H, Romanitan M, Dahlgren LO, Joneberg J, Creson N, Lindholm J, Ye W, Dalianis T, Munck-Wikland E (2006) Human papillomavirus as a risk factor for the increase in incidence of tonsillar cancer. Int J Cancer 119: 2620-2623.
9. Hedman H, Henriksson R (2007) LRIG inhibitors of growth factor signalling-double-edged swords in human cancer? Eur J Cancer 43: 676-682.
10. Hedman H, Lindstrom AK, Tot T, Stendahl U, Henriksson R, Hellberg D (2010) LRIG2 in contrast to LRIG1 predicts poor survival in early-stage squamous cell carcinoma of the uterine cervix. Acta Oncol 49: 812-815.
11. Holmlund C, Nilsson J, Guo D, Starefeldt A, Golovleva I, Henriksson R, Hedman H (2004) Characterization and tissue-specific expression of human LRIG2. Gene 332: 35-43.
12. Johansson M, Oudin A, Tiemann K, Bernard A, Golebiewska A, Keunen O, Fack F, Stieber D, Wang B, Hedman H, Niclou SP (2013) The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status. Neuro Oncol 15(9): 1200-1211.
13. Karlsson T, Mark EB, Henriksson R, Hedman H (2008) Redistribution of LRIG proteins in psoriasis. J Invest Dermatol 128: 1192-1195.
14. Krig SR, Frietze S, Simion C, Miller JK, Fry WH, Rafidi H, Kotelawala L, Qi L, Griffith OL, Gray JW, Carraway 3rd KL, Sweeney C (2011) Lrig1 is an estrogen-regulated growth suppressor and correlates with longer relapse-free survival in ERalpha-positive breast cancer. Mol Cancer Res 9: 1406-1417.
15. Laederich MB, Funes-Duran M, Yen L, Ingalla E, Wu X, Carraway 3rd KL, Sweeney C (2004) The leucine-rich repeat protein LRIG1 is a negative regulator of ErbB family receptor tyrosine kinases. J Biol Chem 279: 47050-47056.
16. Ledda F, Bieraugel O, Fard SS, Vilar M, Paratcha G (2008) Lrig1 is an endogenous inhibitor of Ret receptor tyrosine kinase activation, downstream signaling, and biological responses to GDNF. J Neurosci 28: 39-49.
17. Li F, Yang W, Guo D, Hu Z, Xu H, Ye Z (2011) LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway. Oncol Rep 25: 1629-1637.
18. Lindquist D, Ahrlund-Richter A, Tarjan M, Tot T, Dalianis T (2012) Intense CD44 expression is a negative prognostic factor in tonsillar and base of tongue cancer. Anticancer Res 32: 153-161.
19. Lindstrom AK, Ekman K, Stendahl U, Tot T, Henriksson R, Hedman H, Hellberg D (2008) LRIG1 and squamous epithelial uterine cervical cancer: correlation to prognosis, other tumor markers, sex steroid hormones, and smoking. Int J Gynecol Cancer 18: 312-317.
20. Lindstrom AK, Stendahl U, Tot T, Hellberg D (2007) Associations between ten biological tumor markers in squamous cell cervical cancer and serum estradiol, serum progesterone and smoking. Anticancer Res 27: 1401-1406.
21. Mellin H, Dahlgren L, Munck-Wikland E, Lindholm J, Rabbani H, Kalantari M, Dalianis T (2002) Human papillomavirus type 16 is episomal and a high viral load may be correlated to better prognosis in tonsillar cancer. Int J Cancer 102: 152-158.
22. Mellin HD, Munck-Wikland E, Dahlgren L, Dalianis T (2004) [Occurrence of human papillomavirus is a positive factor in tonsillar cancer. Reduced risk of recurrence and longer survival]. Lakartidningen 101: 2794-27962798.
23. Muller S, Lindquist D, Kanter L, Flores-Staino C, Henriksson R, Hedman H, Andersson S (2013) Expression of LRIG1 and LRIG3 correlates with human papillomavirus status and patient survival in cervical adenocarcinoma. Int J Oncol 42: 247-252.
24. Nasman A, Attner P, Hammarstedt L, Du J, Eriksson M, Giraud G, Ahrlund-Richter S, Marklund L, Romanitan M, Lindquist D, Ramqvist T, Lindholm J, Sparen P, Ye W, Dahlstrand H, Munck-Wikland E, Dalianis T (2009) Incidence of human papillomavirus (HPV) positive tonsillar carcinoma in Stockholm, Sweden: an epidemic of viral-induced carcinoma? Int J Cancer 125: 362-366.
25. Nasman A, Nordfors C, Grun N, Munck-Wikland E, Ramqvist T, Marklund L, Lindquist D, Dalianis T (2013) Absent/low CD44 intensity and positive human papillomavirus (HPV) status in oropharyngeal squamous cell carcinoma indicates a very high survival. Cancer Med 2(4): 507-518.
26. Nilsson J, Starefeldt A, Henriksson R, Hedman H (2003) LRIG1 protein in human cells and tissues. Cell Tissue Res 312: 65-71.
27. Nilsson J, Vallbo C, Guo D, Golovleva I, Hallberg B, Henriksson R, Hedman H (2001) Cloning, characterization, and expression of human LIG1. Biochem Biophys Res Commun 284: 1155-1161.
28. Pignon JP, Le Maitre A, Maillard E, Bourhis J (2009) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 92: 4-14.
29. Powell AE, Wang Y, Li YN, Poulin EJ, Means AL, Washington MK, Higginbotham JN, Juchheim A, Prasad N, Levy SE, Guo Y, Shyr Y, Aronow BJ, Haigis KM, Franklin JL, Coffey RJ (2012) The Pan-ErbB negative regulator lrig1 is an intestinal stem cell marker that functions as a tumor suppressor. Cell 149: 146-158.
30. Ramqvist T, Dalianis T (2010) Oropharyngeal cancer epidemic and human papillomavirus. Emerg Infect Dis 16: 1671-1677.
31. Shattuck DL, Miller JK, Laederich M, Funes M, Petersen H, Carraway 3rd KL, Sweeney C (2007) LRIG1 is a novel negative regulator of the Met receptor and opposes Met and Her2 synergy. Mol Cell Biol 27: 1934-1946.
32. Sheu JJ, Lee CC, Hua CH, Li CI, Lai MT, Lee SC, Cheng J, Chen CM, Chan C, Chao SC, Chen JY, Chang JY, Lee CH (2014) LRIG1 modulates aggressiveness of head and neck cancers by regulating EGFR-MAPKSPHK1 signaling and extracellular matrix remodeling. Oncogene 33(11): 1375-1384.
33. Stutz MA, Shattuck DL, Laederich MB, Carraway 3rd KL, Sweeney C (2008) LRIG1 negatively regulates the oncogenic EGF receptor mutant EGFRvIII. Oncogene 27: 5741-5752.
34. Tanemura A, Nagasawa T, Inui S, Itami S (2005) LRIG-1 provides a novel prognostic predictor in squamous cell carcinoma of the skin: immunohistochemical analysis for 38 cases. Dermatol Surg 31: 423-430.
35. Thomasson M,Wang BF, Hammarsten P, Dahlman A, Persson JL, Josefsson A, Stattin P, Granfors T, Egevad L, Henriksson R, Bergh A, Hedman H (2011) LRIG1 and the liar paradox in prostate cancer: a study of the expression and clinical significance of LRIG1 in prostate cancer. Int J Cancer 128: 2843-2852.
36. Wang Y, Poulin E, Coffey R (2013) LRIG1 is a triple threat: ERBB negative regulator, intestinal stem cell marker and tumour suppressor. Br J Cancer 108: 1765-1770.
37. Wu X, Hedman H, Bergqvist M, Bergstrom S, Henriksson R, Gullbo J, Lennartsson J, Hesselius P, Ekman S (2011) Expression of EGFR and LRIG proteins in oesophageal carcinoma with emphasis on patient survival and cellular chemosensitivity. Acta Oncol 51(1): 69-76.
38. Yi W, Holmlund C, Nilsson J, Inui S, Lei T, Itami S, Henriksson R, Hedman H (2011) Paracrine regulation of growth factor signaling by shed leucine-rich repeats and immunoglobulin-like domains 1. Exp Cell Res 317: 504-512.